TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lamotrigine as an Antidepressant Augmentation Agent in Treatment Refractory Unipolar Depression
Brief Summary: This study is intended to evaluate the efficacy and safety of lamotrigine as an antidepressant augmentation agent in a sample of individuals with major depression and a history of both prior non-response and prospective failure to respond to at least one adequate trial of an antidepressant (for a total of two failed trials).


Options:
A: Arm Label: Switching: Bupropion-SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Switching: Bupropion-SR | Arm Label: Augmenting: Antidepressant + Bupropion-SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Augmenting: Antidepressant + Bupropion-SR | Arm Label: Augmenting: Antidepressant + Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Augmenting: Antidepressant + Aripiprazole | Intervention Type: DRUG; Name: Switching: Bupropion-SR; Assigned to Arm(s): Switching: Bupropion-SR | Intervention Type: DRUG; Name: Augmenting: Antidepressant + Bupropion-SR; Assigned to Arm(s): Augmenting: Antidepressant + Bupropion-SR | Intervention Type: DRUG; Name: Augmenting: Antidepressant + Aripiprazole; Assigned to Arm(s): Augmenting: Antidepressant + Aripiprazole
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, Drug: paroxetine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: paroxetine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): 1, 2
C: Arm Label: Vilazodone 10mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 20mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 40mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 10mg, Vilazodone 20mg, Vilazodone 40mg
D: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Computer-Based Cognitive Training and Sleep Quality in Older Adult Insomniacs
Brief Summary: The purpose of this study is to investigate the effect of computerized, home-based cognitive training on sleep quality of older adults with insomnia.


Options:
A: Arm Label: Cognitive training group (Cog); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Arm Label: Physical exercise group (PE); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise | Arm Label: Sequential training group (Seq); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive training, Behavioral: Physical exercise | Arm Label: Dual-task training group (Dual); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive training, Behavioral: Physical exercise | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Cognitive training group (Cog), Dual-task training group (Dual), Sequential training group (Seq) | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): Dual-task training group (Dual), Physical exercise group (PE), Sequential training group (Seq)
B: Arm Label: Nutritional Intervention; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutritional Intervention | Arm Label: Physical Exercise; Type: EXPERIMENTAL; Interventions: Other: Physical Exercise | Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Cognitive Training | Arm Label: Combined; Type: EXPERIMENTAL; Interventions: Other: Combined | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutritional Intervention; Assigned to Arm(s): Nutritional Intervention | Intervention Type: OTHER; Name: Physical Exercise; Assigned to Arm(s): Physical Exercise | Intervention Type: OTHER; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training | Intervention Type: OTHER; Name: Combined; Assigned to Arm(s): Combined | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: cognitive training; Type: EXPERIMENTAL; Interventions: Device: CogniFit Personal Coach® | Intervention Type: DEVICE; Name: CogniFit Personal Coach®; Assigned to Arm(s): cognitive training
D: Arm Label: Standard health counseling at baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional guidance, Behavioral: Exercise, Behavioral: Cognitive training, Other: Reduction of vascular risk factors | Intervention Type: BEHAVIORAL; Name: Nutritional guidance; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: Reduction of vascular risk factors; Assigned to Arm(s): Lifestyle counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Computer-Based Cognitive Training and Sleep Quality in Older Adult Insomniacs
Brief Summary: The purpose of this study is to investigate the effect of computerized, home-based cognitive training on sleep quality of older adults with insomnia.


Options:
A: Arm Label: Computerized Working Memory Training.; Type: SHAM_COMPARATOR; Interventions: Device: Computerized Working Memory Training. | Intervention Type: DEVICE; Name: Computerized Working Memory Training.; Assigned to Arm(s): Computerized Working Memory Training.
B: Arm Label: cognitive training; Type: EXPERIMENTAL; Interventions: Device: CogniFit Personal Coach® | Intervention Type: DEVICE; Name: CogniFit Personal Coach®; Assigned to Arm(s): cognitive training
C: Arm Label: LLM; Type: EXPERIMENTAL; Interventions: Other: LLM | Arm Label: PTC; Type: EXPERIMENTAL; Interventions: Other: FFA | Arm Label: CTC; Type: EXPERIMENTAL; Interventions: Other: Brain Fitness | Arm Label: Passive; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Other: VideoGrade | Intervention Type: OTHER; Name: LLM; Assigned to Arm(s): LLM | Intervention Type: OTHER; Name: FFA; Assigned to Arm(s): PTC | Intervention Type: OTHER; Name: Brain Fitness; Assigned to Arm(s): CTC | Intervention Type: OTHER; Name: VideoGrade; Assigned to Arm(s): Active
D: Intervention Type: PROCEDURE; Name: Computer-based training for Mild Cognitive Impairment (MCI); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Brief Summary: A study to evaluate AGS-1C4D4 administered in combination with Gemcitabine chemotherapy in subjects with Metastatic Pancreatic Cancer.


Options:
A: Arm Label: gemcitabine hydrochloride + IMC-C225; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: gemcitabine hydrochloride | Arm Label: gemcitabine hydrochloride alone; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine hydrochloride | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): gemcitabine hydrochloride + IMC-C225 | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): gemcitabine hydrochloride + IMC-C225, gemcitabine hydrochloride alone
B: Arm Label: 1. Gemcitabine monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gemcitabine | Arm Label: 2. Gemcitabine plus AGS-1C4D4; Type: EXPERIMENTAL; Interventions: Biological: AGS-1C4D4, Biological: Gemcitabine | Intervention Type: BIOLOGICAL; Name: AGS-1C4D4; Assigned to Arm(s): 2. Gemcitabine plus AGS-1C4D4 | Intervention Type: BIOLOGICAL; Name: Gemcitabine; Assigned to Arm(s): 1. Gemcitabine monotherapy, 2. Gemcitabine plus AGS-1C4D4
C: Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: fluorouracil, Radiation: radiation therapy | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: docetaxel, Radiation: radiation therapy | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm 1 | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1, Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fatigue, Physical Functioning, and Quality of Life in Patients With Pancreatic and Periampullary Cancers Following Surgery, Chemotherapy, and/or Radiation Therapy
Brief Summary: The purpose of this pilot study is to determine the effects of a walking program on fatigue, physical functioning and QOL in patients with pancreatic and periampullary cancers who have had surgery or are undergoing adjuvant therapy with chemotherapy (CT) and/or radiation therapy (RT). This pilot study will utilize the walking program developed by Mock et al. (2001), in their investigation of the improvement of fatigue and QOL in breast care patients following surgery who were receiving CT, RT or biotherapy. No studies published to date have utilized a progressive walking program in post-operative pancreas and ampullary cancers to determine if it reduces adverse effects, such as fatigue or improves functionality and QOL scores.


Options:
A: Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Walking Program; Type: EXPERIMENTAL; Interventions: Other: Walking Program | Intervention Type: OTHER; Name: Walking Program; Assigned to Arm(s): Walking Program
B: Arm Label: Exercise in breast cancer survivors; Type: EXPERIMENTAL; Interventions: Behavioral: Combined aerobic and strength exercise training | Arm Label: No exercise in breast cancer survivors; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise in healthy subjects; Type: SHAM_COMPARATOR; Interventions: Behavioral: Combined aerobic and strength exercise training | Intervention Type: BEHAVIORAL; Name: Combined aerobic and strength exercise training; Assigned to Arm(s): Exercise in breast cancer survivors, Exercise in healthy subjects
C: Arm Label: Standard PA Recommendation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telephone Implementation Intention; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Implementation Intention | Arm Label: Self-completed implementation intention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-completed implementation intention | Intervention Type: BEHAVIORAL; Name: Telephone Implementation Intention; Assigned to Arm(s): Telephone Implementation Intention | Intervention Type: BEHAVIORAL; Name: Self-completed implementation intention; Assigned to Arm(s): Self-completed implementation intention
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria
Brief Summary: Antimalarial drug resistance is increasing nearly everywhere in the tropical world, confounding global attempts to "Roll Back Malaria." South East Asia has the most resistant malaria parasites in the world. This has limited the options for treatment in this region.

Artemisinin-based combination therapy is now the recommended treatment for uncomplicated falciparum malaria. The success of this policy change in practice will depend on the efficacy of the components of the combination used, the population coverage achieved, high levels of adherence to treatment, low cost of the drugs, and preferably the drugs in a combination treatment should be formulated in a single tablet, to prevent one drug being taken without the partner drug. Until recently there were only two artemisinin-based fixed combinations available, artemether-lumefantrine and dihydroartemisinin-piperaquine; and only the former has international registration. More fixed combinations are needed urgently.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
B: Arm Label: 3 day therapy; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin piperaquine | Arm Label: 2 day therapy; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin piperaquine | Intervention Type: DRUG; Name: Dihydroartemisinin piperaquine; Assigned to Arm(s): 2 day therapy, 3 day therapy
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1
D: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria
Brief Summary: Antimalarial drug resistance is increasing nearly everywhere in the tropical world, confounding global attempts to "Roll Back Malaria." South East Asia has the most resistant malaria parasites in the world. This has limited the options for treatment in this region.

Artemisinin-based combination therapy is now the recommended treatment for uncomplicated falciparum malaria. The success of this policy change in practice will depend on the efficacy of the components of the combination used, the population coverage achieved, high levels of adherence to treatment, low cost of the drugs, and preferably the drugs in a combination treatment should be formulated in a single tablet, to prevent one drug being taken without the partner drug. Until recently there were only two artemisinin-based fixed combinations available, artemether-lumefantrine and dihydroartemisinin-piperaquine; and only the former has international registration. More fixed combinations are needed urgently.


Options:
A: Intervention Type: DRUG; Name: primaquine; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
C: Arm Label: DHP+PQ; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin/piperaquine + primaquine | Arm Label: AS-AQ +PQ; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate-amodiaquine + primaquine | Intervention Type: DRUG; Name: Dihydroartemisinin/piperaquine + primaquine; Assigned to Arm(s): DHP+PQ | Intervention Type: DRUG; Name: Artesunate-amodiaquine + primaquine; Assigned to Arm(s): AS-AQ +PQ
D: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria
Brief Summary: Antimalarial drug resistance is increasing nearly everywhere in the tropical world, confounding global attempts to "Roll Back Malaria." South East Asia has the most resistant malaria parasites in the world. This has limited the options for treatment in this region.

Artemisinin-based combination therapy is now the recommended treatment for uncomplicated falciparum malaria. The success of this policy change in practice will depend on the efficacy of the components of the combination used, the population coverage achieved, high levels of adherence to treatment, low cost of the drugs, and preferably the drugs in a combination treatment should be formulated in a single tablet, to prevent one drug being taken without the partner drug. Until recently there were only two artemisinin-based fixed combinations available, artemether-lumefantrine and dihydroartemisinin-piperaquine; and only the former has international registration. More fixed combinations are needed urgently.


Options:
A: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-Lumefantrine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: Artemether-Lumefantrine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Artekin / Coartemther; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amodiaquine-artesunate (ASAQ) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: dihydroartemisinin-piperaquine (DHAPQ) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: artemether-lumefantrine (AL) | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS) | Intervention Type: DRUG; Name: amodiaquine-artesunate (ASAQ); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine (DHAPQ); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: artemether-lumefantrine (AL); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS); Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria
Brief Summary: Antimalarial drug resistance is increasing nearly everywhere in the tropical world, confounding global attempts to "Roll Back Malaria." South East Asia has the most resistant malaria parasites in the world. This has limited the options for treatment in this region.

Artemisinin-based combination therapy is now the recommended treatment for uncomplicated falciparum malaria. The success of this policy change in practice will depend on the efficacy of the components of the combination used, the population coverage achieved, high levels of adherence to treatment, low cost of the drugs, and preferably the drugs in a combination treatment should be formulated in a single tablet, to prevent one drug being taken without the partner drug. Until recently there were only two artemisinin-based fixed combinations available, artemether-lumefantrine and dihydroartemisinin-piperaquine; and only the former has international registration. More fixed combinations are needed urgently.


Options:
A: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
B: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine + artesunate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): N/A
C: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)
D: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2

Answer: C